Transgene is advancing its individualized neoantigen therapeutic platform, signaling continued industry focus on personalized cancer vaccines.GlobeNewswire
This development highlights the commercialization efforts within the neoantigen space as companies seek to translate clinical potential into marketable treatments.
Nothing published in the last 14 days cleared the bar. Below is the most relevant background we're tracking.
Relevant work from earlier we're still surfacing — not today's news.